Evidence map›Paper›PMID 39488682›Full record

Trial reportCardiovascular diabetology2024

Biomarkers of glucose-insulin homeostasis and incident type 2 diabetes and cardiovascular disease: results from the Vitamin D and Omega-3 trial.

Frank Qian, Yanjun Guo, Chunying Li, Yanyan Liu, Heike Luttmann-Gibson, Natalya Gomelskaya, Olga V Demler, Nancy R Cook, I-Min Lee, Julie E Buring and 6 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cardiovascular diabetology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01169259 (Vitamin D and Omega-3 Trial), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01169259 phase3active not recruitingnot on this map

Vitamin D and Omega-3 Trial (VITAL)

TypeinterventionalSponsorBrigham and Women's HospitalRan2010 to 2026Enrolled25,871ConditionsCancer, Cardiovascular DiseaseArmsvitamin D3, omega-3 fatty acids (fish oil), Vitamin D3 placebo, Fish oil placebo
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Frank Qian *Division of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Yanjun Guo *Division of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Chunying LiDivision of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Yanyan LiuDivision of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Heike Luttmann-GibsonDivision of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Natalya GomelskayaDivision of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Olga V DemlerDivision of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Nancy R CookDivision of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
I-Min LeeDivision of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Julie E BuringDivision of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Julia LarsenQuest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA.
Jennifer BoringQuest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA.
Michael J McPhaulQuest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA.
JoAnn E MansonDivision of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Aruna D Pradhan *Division of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Samia Mora *Division of Preventive Medicine, Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. smora@bwh.harvard.edu.

Funding

The VITamin D and OmegA-3 TriaL (VITAL): Post-Intervention Follow-UpR01AT011729 · NCCIH · BRIGHAM AND WOMEN'S HOSPITAL · 2021 to 2025
$1.6M
Patient Centered Approaches to Preventing ASCVD EventsK24HL136852 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · 2022 to 2025
$247k
CHD Risk and Metabolomic Profiles of Discordant LipidsK01HL135342 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Olga Demler · 2021 to 2021
$178k
NCCIH NIH HHS R01 AT011729NHLBI NIH HHS K01 HL135342NHLBI NIH HHS K24 HL136852NHLBI NIH HHS R21 HL167173NIH HHS R01AT011729
6 · The paper itself

Abstract

backgroundDysglycemia and insulin resistance increase type 2 diabetes (T2D) and cardiovascular disease (CVD) risk, yet associations with specific glucose-insulin homeostatic biomarkers have been inconsistent. Vitamin D and marine omega-3 fatty acids (n-3 FA) may improve insulin resistance. We sought to examine the association between baseline levels of insulin, C-peptide, HbA1c, and a novel insulin resistance score (IRS) with incident cardiometabolic diseases, and whether randomized vitamin D or n-3 FA modify these associations.

methodsVITamin D and OmegA-3 TriaL (NCT01169259) was a randomized clinical trial testing vitamin D and n-3 FA for the prevention of CVD and cancer over a median of 5.3 years. Incident cases of T2D and CVD (including cardiovascular death, myocardial infarction, stroke, and coronary revascularization) were matched 1:1 on age, sex, and fasting status to controls. Conditional logistic regressions adjusted for demographic, clinical, and adiposity-related factors were used to assess the adjusted odds ratio (aOR) per-standard deviation (SD) and 95%CI of baseline insulin, C-peptide, HbA1c, and IRS (Insulin×0.0295 + C-peptide×0.00372) with risk of T2D, CVD, and coronary heart disease (CHD).

resultsWe identified 218 T2D case-control pairs and 715 CVD case-control pairs including 423 with incident CHD. Each of the four biomarkers at baseline was separately associated with incident T2D, aOR (95%CI) per SD increment: insulin 1.46 (1.03, 2.06), C-peptide 2.04 (1.35, 3.09), IRS 1.72 (1.28, 2.31) and HbA1c 7.00 (3.76, 13.02), though only HbA1c remained statistically significant with mutual adjustments. For cardiovascular diseases, we only observed significant associations of HbA1c with CVD (1.19 [1.02, 1.39]), and IRS with CHD (1.25 [1.04, 1.50]), which persisted after mutual adjustment. Randomization to vitamin D and/or n-3 FA did not modify the association of these biomarkers with the endpoints.

conclusionsEach of insulin, C-peptide, IRS, and HbA1c were associated with incident T2D with the strongest association noted for HbA1c. While HbA1c was significantly associated with CVD risk, a novel IRS appears to be associated with CHD risk. Neither vitamin D nor n-3 FA modified the associations between these biomarkers and cardiometabolic outcomes.

Indexed as

BiomarkersBlood GlucoseCardiovascular DiseasesC-PeptideDiabetes Mellitus, Type 2Fatty Acids, Omega-3Glycated HemoglobinInsulinInsulin ResistanceVitamin DAgedDietary SupplementsDouble-Blind MethodFemaleHomeostasisHumansBiomarkersBlood GlucoseC-PeptideFatty Acids, Omega-3Glycated Hemoglobinhemoglobin A1c protein, humanInsulinVitamin DCardiovascular diseaseInsulin resistanceOmega-3 fatty acidsType 2 diabetesVitamin D

Identifiers

PMID39488682
PMCPMC11531120

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.